Tau Protein Expressing Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tau protein expressing neurons represent a critical population in the study of Alzheimer's disease (AD) and related tauopathies. These neurons are characterized by the presence of tau (MAPT - Microtubule-Associated Protein Tau), a microtubule-stabilizing protein that plays essential roles in normal neuronal function but can form toxic aggregates that drive neurodegeneration.
| Property |
Value |
| Category |
Cytoskeletal Proteins |
| Location |
Axons, cell body, NFTs |
| Protein |
Tau (MAPT) |
| Function |
Microtubule stabilization, axonal transport |
| Associated Diseases |
Alzheimer's Disease, Frontotemporal Dementia, Progressive Supranuclear Palsy, Corticobasal Degeneration, Chronic Traumatic Encephalopathy |
| Taxonomy |
ID |
Name / Label |
| Allen Brain Cell Atlas |
Search |
Tau Protein Expressing Neurons |
| Cell Ontology (CL) |
Search |
Check classification |
| Human Cell Atlas |
Search |
Check expression data |
| CellxGene Census |
Search |
Check cell census |
Tau is primarily located in axons where it binds to microtubules and:
- Stabilizes microtubule structure: Prevents depolymerization and maintains axonal integrity
- Facilitates axonal transport: Provides tracks for kinesin and dynein motor proteins
- Maintains neuronal polarity: Distinguishes axons from dendrites
- Regulates microtubule dynamics: Modulates polymerization and stability
Tau also localizes to synapses where it participates in:
- Presynaptic functions: Regulates synaptic vesicle release and recycling
- Postsynaptic signaling: Interacts with postsynaptic receptors and scaffolding proteins
- Synaptic plasticity: Involved in learning and memory processes
- Activity-dependent release: Tau can be released from synapses in an activity-dependent manner
During neuronal development, tau:
- Promotes axon specification and outgrowth
- Guides cytoskeletal organization in growing neurons
- Supports dendritic arborization through microtubule regulation
The MAPT gene produces six tau isoforms in the adult human brain through alternative splicing of exons 2, 3, and 10:
- 3-repeat tau (3R): Lacks exon 10, binds one microtubule
- 4-repeat tau (4R): Includes exon 10, binds two microtubules
- Isoform ratio: 3R:4R ratio is ~1:1 in normal adult brain
The balance between 3R and 4R tau is critical - imbalances lead to tauopathy.
Tau is subject to numerous post-translational modifications:
- Phosphorylation: Up to 85 potential phosphorylation sites; hyperphosphorylation is pathological
- Acetylation: Promotes aggregation by reducing tau's ability to bind microtubules
- Truncation: Proteolytic cleavage generates aggregation-prone fragments
- O-GlcNAcylation: Metabolic regulation, competes with phosphorylation
- Sumoylation: Influences aggregation and clearance
¶ Hyperphosphorylation and Aggregation
In Alzheimer's disease and tauopathies, tau becomes hyperphosphorylated and aggregates:
- Phosphorylation at disease-associated sites: Kinases (GSK3β, CDK5) overactivate
- Loss of microtubule binding: Hyperphosphorylated tau dissociates from microtubules
- Oligomer formation: Soluble toxic oligomers form
- NFT formation: Paired helical filaments aggregate into neurofibrillary tangles
Neurofibrillary tangles (NFTs) are intracellular aggregates of hyperphosphorylated tau:
- Braak staging: Correlates with disease progression (I-VI)
- Neuronal loss: NFTs are associated with neuronal death
- Spread pattern: Follows neural connectivity pathways
Tau pathology drives neuronal dysfunction through:
- Microtubule disruption: Impaired axonal transport
- Synaptic loss: Reduced synaptic proteins, impaired plasticity
- Mitochondrial dysfunction: Energy deficits
- ER stress: Protein homeostasis disruption
- Neuroinflammation: Glial activation
- Exosomal release: Propagation to connected neurons
Specific neurons are particularly vulnerable to tau pathology:
- Entorhinal cortex neurons: Early involvement, critical for memory
- Hippocampal CA1 pyramidal neurons: Essential for memory formation
- Layer II entorhinal cortex neurons: Early tau pathology in AD
- Subcortical nuclei: Locus coeruleus, dorsal raphe
- Specific cortical pyramidal neurons: Layer V neurons
Tau-targeted therapies include:
- Anti-aggregation agents: Prevent tau misfolding and aggregation
- Kinase inhibitors: Reduce pathological phosphorylation (GSK3β, CDK5)
- Phosphatase activators: Promote tau dephosphorylation
- Immunotherapy: Active and passive vaccines targeting tau
- Microtubule stabilizers: Restore axonal transport
- Tau degradation enhancers: Promote autophagy and proteasomal clearance
Tau in cerebrospinal fluid and blood serves as a biomarker:
- Total tau: Reflects neuronal damage
- Phosphorylated tau (p-tau181, p-tau217): Disease-specific markers
- p-tau217: High specificity for AD, correlates with amyloid pathology
- iPSC-derived neurons: From AD patients with MAPT mutations
- Primary neuron cultures: Overexpression or knock-in models
- Tau fibril seeding models: Introduce pathological tau to healthy neurons
- Transgenic mice: rTg4510, P301S, 3xTg-AD
- Knockin models: Humanized tau with pathogenic mutations
- Viral vector models: AAV-mediated tau overexpression
The study of Tau Protein Expressing Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.